| Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma O Zavidij, NJ Haradhvala, TH Mouhieddine, R Sklavenitis-Pistofidis, S Cai, ... Nature cancer 1 (5), 493-506, 2020 | 258 | 2020 |
| Molecular bottlebrush prodrugs as mono-and triplex combination therapies for multiple myeloma A Detappe, HVT Nguyen, Y Jiang, MP Agius, W Wang, C Mathieu, NK Su, ... Nature nanotechnology 18 (2), 184-192, 2023 | 38 | 2023 |
| Progression signature underlies clonal evolution and dissemination of multiple myeloma YJ Shen, Y Mishima, J Shi, R Sklavenitis-Pistofidis, RA Redd, ... Blood, The Journal of the American Society of Hematology 137 (17), 2360-2372, 2021 | 31 | 2021 |
| Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma R Sklavenitis-Pistofidis, MP Aranha, RA Redd, J Baginska, ... Cancer Cell 40 (11), 1358-1373. e8, 2022 | 21 | 2022 |
| Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma M Bustoros, O Nadeem, AS Sperling, G Bianchi, L Ardente, RA Redd, ... Blood 134, 580, 2019 | 13 | 2019 |
| MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology AK Dutta, JB Alberge, ED Lightbody, CJ Boehner, A Dunford, ... Cancer discovery 13 (2), 348-363, 2023 | 10 | 2023 |
| Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia S Tahri, TH Mouhieddine, R Redd, L Lampe, KI Nilsson, H El-Khoury, ... Blood Advances 6 (7), 2230-2235, 2022 | 10 | 2022 |
| Novel cytokine–antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma Y Chu, G Nayyar, NK Su, JM Rosenblum, P Soon-Shiong, J Lee, JT Safrit, ... Journal for Immunotherapy of Cancer 8 (2), 2020 | 10 | 2020 |
| A phase II study of daratumumab in patients with high-risk MGUS and low-risk smoldering multiple myeloma: first report of efficacy and safety O Nadeem, R Redd, LV Stampleman, JV Matous, AJ Yee, JA Zonder, ... Blood 134, 1898, 2019 | 7 | 2019 |
| Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020 May; 1 (5): 493-506 O Zavidij, NJ Haradhvala, TH Mouhieddine, R Sklavenitis-Pistofidis, S Cai, ... Personalized Medicine’s Coming of Age 1, 0 | 6 | |
| Clonal Hematopoiesis Is Associated with Increased Risk of Progression of Asymptomatic Waldenström Macroglobulinemia S Tahri, TH Mouhieddine, RA Redd, LM Lampe, K Nillson, NK Su, ... Blood 138, 2678, 2021 | 5 | 2021 |
| Single-cell RNA-sequencing identifies immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma R Sklavenitis-Pistofidis, AK Dutta, S Ujwary, RA Redd, A Savell, L Fléchon, ... Blood 138, 330, 2021 | 2 | 2021 |
| 2B8T2M, A Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody Significantly Enhanced Expanded Natural Killer Cells Ctotoxicity Against … Y Chu, NK Su, EK Jeng, S Alter, PR Rhode, G Nayyar, M Barth, DA Lee, ... | 2 | 2018 |
| High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients ED Lightbody, H Keshishian, H El-Khoury, AK Dutta, H Barr, J Barbagallo, ... Blood 140 (Supplement 1), 4303-4304, 2022 | 1 | 2022 |
| Single-cell RNA-sequencing of 245 tumor samples from patients with MGUS and smoldering multiple myeloma reveals novel insights into malignant plasma cell biology J Tsuji, ED Lightbody, R Sklavenitis-Pistofidis, MP Agius, M Rahmat, ... Blood 140 (Supplement 1), 254-255, 2022 | 1 | 2022 |
| Single-cell RNA sequencing of rare circulating tumor cells in precursor myeloma patients reveals molecular underpinnings of tumor cell circulation ED Lightbody, DT Firer, R Sklavenitis-Pistofidis, J Tsuji, MP Agius, ... Blood 140 (Supplement 1), 602-603, 2022 | 1 | 2022 |
| Non-Invasive Liquid Biopsy to Quantify and Molecularly Characterize Circulating Multiple Myeloma Cells in the Assessment of Precursor Disease Pathology AK Dutta, ED Lightbody, Z Lin, JB Alberge, R Sklavenitis-Pistofidis, ... Blood 138, 78, 2021 | 1 | 2021 |
| Therapeutic effects of a novel fusion of ALT-803, an IL-15 superagonist, with 4 single-chains of anti-CD20 antibody (2B8T2M) in combination with expanded natural killer cells … Y Chu, NK Su, S Alter, EK Jeng, PR Rhode, M Barth, D Lee, HC Wong, ... Biology of Blood and Marrow Transplantation 24 (3), S75-S76, 2018 | 1 | 2018 |
| Regulation of Cytokine Release and Anti-Tumor Effect of Anti-CD20 CAR Modified Expanded Natural Killer Cells by ALT-803, an Il-15 Superagonist Y Chu, NK Su, C Hamby, EK Jeng, S Alter, M Barth, HC Wong, DA Lee, ... | 1 | 2018 |
| Therapeutic effects of a novel fusion of ALT-803, an IL-15 superagonist, with 4 single-chains of anti-CD20 antibody (2B8T2M) in combination with expanded natural killer cells … Y Chu, NK Su, S Alter, EK Jeng, PR Rhode, MJ Barth, DA Lee, HC Wong, ... Blood 130, 3587, 2017 | 1 | 2017 |
